Zalicus gains on publication of data. Savient launches gout drug Print E-mail
By BioMedReports.com Staff   
Friday, 25 February 2011 19:42
Below is a look at some of the headlines for companies that made news in the healthcare sector on February 25, 2011.


Shares of Zalicus Inc. (NASDAQ:ZLCS) moved higher today after the company announced the publication of preclinical data in the journal PAIN. The paper describes the activity of Z212, a novel proprietary small organic compound that acts to modulate Nav1.7 and Nav1.8 sodium channels and to reduce neuropathic pain by targeting the hyper-excitability associated with chronic pain signaling pathways. Through its unique mechanism of action, Z212 has been shown to both reduce the excitability of neurons and reverse pain hypersensitivity in preclinical models. Zalicus is utilizing its ion channel discovery platform and scientific expertise to develop a pipeline of novel, orally active compounds targeting critical N-type and T-type calcium and selected sodium channels implicated in chronic pain.

Zalicus’s most advanced preclinical ion channel product candidate, Z944, a novel T-type calcium channel blocker, has been selected to advance into IND-enabling toxicology studies prior to the initiation of a Phase 1 study in 2011. Z212 and multiple other preclinical compounds have been identified and are being evaluated for additional clinical starts in 2011.

In the paper entitled, "A novel slow-inactivation-specific ion channel modulator attenuates neuropathic pain," Hildebrand et al., PAIN (2011), Zalicus researchers describe the design, synthesis and activity of the unique sodium channel pain blocking compound Z212 to preferentially attenuate hyperexcitable neurons while largely sparing normally firing neurons.

"By targeting the sodium channels in the peripheral and central nociceptive signaling pathways through its unique mechanism of action, Z212 has the potential to become a safe and effective treatment for chronic inflammatory and neuropathic pain," commented Mark H.N. Corrigan, MD, President and CEO of Zalicus. "With the addition of selected sodium channel targets to its screening platform Zalicus continues to utilize its considerable expertise in ion channels to develop a pipeline of novel, orally available agents that address these attractive targets for pain intervention."

Shares of Zalicus gained 15 cents or 7.28% to $2.21.


Savient Pharmaceuticals, Inc. (Nasdaq:SVNT) today announced the official full U.S. commercial launch of KRYSTEXXA, which has been approved by the FDA for the treatment of chronic gout in adult patients refractory to conventional therapy. KRYSTEXXA is now the first and only therapy available to address this unmet medical need.

"Since receiving FDA approval for KRYSTEXXA, we have focused on preparing for a successful U.S. launch," said John H. Johnson, Chief Executive Officer of Savient. "Our sales force has completed very thorough and extensive training. We are excited to deploy this highly talented and biologics experienced team into their territories. There has never been a more exciting time in the history of Savient, nor for the chronic gout patients, who have waited so long for a therapy that has the potential to change the course of their lives."

Shares of Savient added 39 cents or 4% to $9.85.

Cadence Pharmaceuticals, Inc. (Nasdaq:CADX) , a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its fourth quarter and full year ended December 31, 2010 financial results on Friday, March 4, 2011.

GeoVax Labs, Inc. (OTC Bulletin Board:GOVX), an Atlanta-based biotechnology company that creates, develops, and tests innovative HIV/AIDS vaccines, today announced its financial results for the fourth quarter and year ended December 31, 2010.

GlaxoSmithKline (NYSE:GSK) today announced that the United States Food and Drug Administration (FDA) granted full approval for PROMACTA® (eltrombopag), an oral tablet that can raise platelet counts in patients with the rare blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.

Hiru Corporation (PINK SHEETS:HIRU) subsidiary Jiangxi Shaungshi AHP recently held training seminars in Beijing, China.

Imagenetix, Inc. (OTC Bulletin Board:IAGX) announced today results for the three and nine months ended December 31, 2010.

Kendle (Nasdaq:KNDL) announced today it will release its fourth quarter and full-year 2010 financial results after the market closes on Wednesday, March 2, 2011.

Michelex Corporation (PINKSHEETS: MLXO) President Mr. Albert Laclé is pleased to announce the shipment of the first batch of products from Pristine Pharma Corporation's newly constructed manufacturing facility in Massena, NY, on Feb 23, 2011, to an export distributor for Caribbean countries.

TimeShare Holdings, Inc. (OTCQB: TMSH) is pleased to announce that TMSH and Western International External Corporation Ltd. (WIEC) have entered into a Joint Venture agreement with the Shandong Taishan Real Estate Co., Ltd. to finance, construct and secure the long-term management and operation of the Panlongshanshui Senior Healthy Living Center in Jinan City, Shandong Province, China.

Verenium Corporation (Nasdaq:VRNM), a pioneer in the development and commercialization of high-performance industrial enzyme solutions, today announced a series of changes within its senior management team to take effect March 31: Carlos Riva, currently Director, President and Chief Executive Officer, will be retiring from his position at the Company.

VIVUS, Inc. (Nasdaq:VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at three investment conferences during the month of March.

 




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter